Evelia Johnston of The Michael J. Fox Foundation for Parkinson’s Research speaks about venture philanthropy and how the MJFF works to fulfill the unmet funding needs of R&D targeting Parkinson’s Disease.
Life Science Nation founder Dennis Ford gives insight into fundraising and tips for approaching investors.
Dr. Jak Knowles of CureDuchenne Ventures sheds light on Duchenne Muscular Dystrophy, CureDuchenne’s role in seeking a cure, and its non-dilutive and venture philanthropy funding models supporting R&D.
Summit Overview –
Join life science industry leaders in a full day of non-dilutive funding activities at the 11th Annual Non-dilutive Funding Summit, taking place on Wednesday January 13th, 2016 in San Francisco.
This year the summit is proud to host Colonel Russell E. Coleman, Ph.D., Joint Project Manager, Medical Countermeasure Systems Assistant Corps Chief (Medical Service Corps) for Preventive Medicine Entomology. Colonel Coleman will discuss “The Dilemma in the Development of Medical Countermeasures against Chemical and Biological Weapons: An unpredictable threat and products we hope will never be used.”
Attend presentations and panel discussions featuring NIH representatives from NIAID, NIBIB, NINDS, and NCI. Also presenting is Ram May-Ron, Managing Partner, FreeMind Group who will provide FreeMind’s annual outlook at the non-dilutive funding lanscape; trends and opportunities.
See full agenda for details on all the activities during the day.
Agenda at a Glance
08:00 – 08:30
Pre-Conference Workshop – How to Build a Non-Dilutive Funding Strategy
08:00 – 09:00
Breakfast and Networking
09:00 – 09:30
FreeMind Group Presentation
09:45 – 10:30
Keynote Address – US Army Presentation
10:30 – 11:15
11:30 – 12:00
Round Tables – Meet with Colonel Coleman and Dr Kurilla
12:00 – 1:00
1:30 – 2:00
National MS Society Presentation
2:00 – 2:30
2:30 – 3:00
3:00 – 4:30
Panel Discussion – NIAID, US Army, NIBIB, NCI, NINDS, MS Society
Presentations by the FreeMind Group, Life Science Nation and Jameson & Company
Boston Cambridge Marriott – 50 Broadway, Cambridge, MA
April 27th, 2015
Join the FreeMind Group, LSN and Jameson and Company for a day of educational programing for life science executives on the topics of non-dilutive funding and post award management, and fund raising and branding.
|08:00 – 08:30||Light Breakfast and Networking|
|08:30 – 09:15||FreeMind Group Presentation – Non-Dilutive Funding; A Strategic Financial ToolPresenter: Ram May-Ron, Managing Partner, FreeMind Group
|09:30 – 10:30||Life Science Nation Presentation – Entrepenurial BootcampPresenter: Dennis Ford, CEO Life Science Nation
|10:45 – 11:30||Post Aawrd ManagementPresenter: Ed Jameson, Managing Member, Jameson & Company CPA
|11:30 – onwards||1×1 meetings with Ram May-Ron, Dennis Ford and/or Ed JamesonPlease schedule in advanceTo schedule a meeting with:
Ram May-Ron, please email: [email protected]
Dennis Ford, please email: [email protected]
Ed Jameson, please email: [email protected]
CEO, Life Science Nation
The Bootcamp will be a top-to-bottom lesson on outbound fundraising in which we choose two attending companies and generate a global target list of relevant investors for them. The Fundraising Bootcamp will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and outbound fundraising.
Dr. Rajesh Ranganathan
Director of the Office of Translational Research at NINDS
The Office of Translational Research (OTR) at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, facilitates the preclinical discovery and development of new therapeutic interventions for neurological disorders. The OTR offers five programs that support the design, implementation, and management of research activities to critical translational challenges in neurology. The programs include: 1) the Anticonvulsant Screening Program (ASP), 2) Blueprint Network (BPN), 3) The Countermeasures Against Chemical Threats Program (CA), 4) Cooperative Research to Enable and Advance Translational Enterprises (CREATE), and 5) The Small Business Innovation Research Program (SBIR). The OTR provides funding (approximately $100 million annually) in grants and resources to industry and university researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Significant emphasis is placed on engaging other stakeholders, such as pharmaceutical, biotechnology, venture capital, and patient advocacy organizations to ensure that projects are adequately de-risked to accelerate downstream investments and to develop much-needed therapies for people suffering from neurological disorders. The keynote talk will provide overiews on these programs and how they can link to successful development outcomes. This will be an excellent opportunity to better understand how to successfully navigate the application process and learn about organizations that have advanced projects using NINDS support. We will also provide information on our funded programs and work with potential interested parties to make the appropriate introductions to our funded investigators.
Presenter: Dr Shy Shorer – Director, Office of Clinical Research Affairs (OCRA) – DMID, National Institute of Allergy and Infectious Diseases (NIAID)
In his talk, Dr. Shy Shorer, the Director of the Office of Clinical Research Affairs (OCRA) in the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID) will describe the services available to the research community. DMID provides plethora of services to the infectious disease research community that encompass the entire spectrum of product development. In the transitional research arena DMID provides pre-clinical and clinical services to the research community, free of charge. Those include biological research resources, bioinformatics, in vitro and in vivo testing and screening of potential therapeutic and vaccines, manufacturing, assistance in creating clinical development plans to name a few. Dr. Shorer will concentrate on the clinical opportunities available for the research community including the Investigator Initiated Clinical Trial (IICT) grants program, access to the Phase I Clinical Trial Unit, access to the Vaccine and Therapeutic Evaluation Units (VTEUs) as well as specialized clinical trial programs.
Watch a presentation by Ram May-Ron, Managing Partner, FreeMind Group.
Ram presented during the 10th Annual Non-dilutive Funding Summit that took place in San Francisco on January 14, 2015. In his presentation Ram discussed the state of the non-dilutive funding market as it relates to industry and the Billions of dollars that are available. Ram also took a more strategic look at such a funding effort with an emphasis on a multi-submission funding strategy.
The Non-Dilutive Funding Summit came together on January 14th, 2015 for the tenth consecutive year. The ~300 life science executives who attended the day long activities learned about Neuroscience Funding Opportunities related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS) from Dr Rajesh Ranganathan, as well as a detailed description of the resources available to industry by the National Institute of Allergy and Infectious Diseases (NIAID) from Dr Shy Shorer.
Dr Ranganathan described the newly issued CREATE funding opportunities and emphasized the interest NINDS has with solutions stemming from the industry side as well as urged companies to approach the NINDS before submitting a grant proposal. The purpose would be to received feedback and perhaps guidance on how to maximize the chances for an award.
During the event a panel discussion with CEOs of companies who have been successful in winning awards from $150,000 to $21,000,0000 shared their insight into the makings of a winning application. All agreed external help is warranted (coincidentally all received such assistance from the FreeMind Group) and that a diligent approach together with a sound multi-submission strategy is the way to go. FreeMind’s VP Ayal Ronen concluded the panel with pointing out that all awards have one thing in common which is that they all were submitted at certain point in time. The crowd erupted in laughter and the summit adjourned.
Jokes aside, FreeMind’s Managing Partner Ram May-Ron in his presentation focused on a balanced funding campaign where Non-Dilutive Funding must be an integral part of any funding effort. In fact, for every dollar one raises from non-dilutive sources, one can expect $8.38 dollars investment by the private sector. Meghan Norvell from nanoMR agreed interest from potential buyers increased dramatically following the award from BARDA.
Join us next year at the 11th Annual Non-Dilutive Funding Summit!